SFCM
CYTK icon

Seven Fleet Capital Management’s Cytokinetics CYTK Stock Holding History

Seven Fleet Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Buy
118,240
+56,971
+93% +$4.09M 1.66% 12
2026
Q1 		$4.04M Buy
61,269
+50,934
+493% +$3.24M 1.27% 19
2025
Q4 		$657K Buy
+10,335
New +$643K 0.44% 41

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Seven Fleet Capital Management's CYTK Position: Q2 2026 in Review

Seven Fleet Capital Management increased its Cytokinetics (CYTK) stake by 93% in Q2 2026, buying an estimated $4.09M and bringing the position to 118,240 shares worth $10.1M. The position accounts for 1.66% of the portfolio, ranked #12.

Seven Fleet Capital Management first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Seven Fleet Capital Management held 118,240 shares of Cytokinetics worth $10.1M as of Q2 2026.
  • Seven Fleet Capital Management bought 56,971 Cytokinetics shares in Q2 2026, an estimated $4.09M.
  • Cytokinetics made up 1.66% of Seven Fleet Capital Management's portfolio in Q2 2026, its #12 holding.
  • Seven Fleet Capital Management first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.